79 related articles for article (PubMed ID: 8607025)
21. Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer.
Rancourt C; Bergeron C; Lane D; Garon G; Piché A
Cytotherapy; 2003; 5(6):509-22. PubMed ID: 14660047
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter.
Määttä AM; Korja S; Venhoranta H; Hakkarainen T; Pirinen E; Heikkinen S; Pellinen R; Mäkinen K; Wahlfors J
Int J Mol Med; 2006 Nov; 18(5):901-8. PubMed ID: 17016620
[TBL] [Abstract][Full Text] [Related]
23. Co-transduction of herpes simplex virus thymidine kinase gene and human interleukin-2 gene into mouse ovarian cancer cell line, OVHM.
Yamaguchi Y; Takashima I; Hihara J; Ohta K; Shimizu K; Minami K; Yoshida K; Toge T
Int J Mol Med; 2000 Aug; 6(2):185-90. PubMed ID: 10891564
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy.
Crittenden M; Gough M; Chester J; Kottke T; Thompson J; Ruchatz A; Clackson T; Cosset FL; Chong H; Diaz RM; Harrington K; Alvarez Vallina L; Vile R
Cancer Res; 2003 Jun; 63(12):3173-80. PubMed ID: 12810645
[TBL] [Abstract][Full Text] [Related]
25. Pigment cell lineage-specific expression activity of the ascidian tyrosinase-related gene.
Toyoda R; Kasai A; Sato S; Wada S; Saiga H; Ikeo K; Gojobori T; Numakunai T; Yamamoto H
Gene; 2004 May; 332():61-9. PubMed ID: 15145055
[TBL] [Abstract][Full Text] [Related]
26. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.
Barker SD; Coolidge CJ; Kanerva A; Hakkarainen T; Yamamoto M; Liu B; Rivera AA; Bhoola SM; Barnes MN; Alvarez RD; Curiel DT; Hemminki A
J Gene Med; 2003 Apr; 5(4):300-10. PubMed ID: 12692864
[TBL] [Abstract][Full Text] [Related]
27. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
28. Adenovirus E1a protein enhances the cytotoxic effects of the herpes thymidine kinase-ganciclovir system.
Parada C; Hernández Losa J; Guinea J; Sánchez-Arévalo V; Fernández Soria V; Alvarez-Vallina L; Sánchez-Prieto R; Ramón y Cajal S
Cancer Gene Ther; 2003 Feb; 10(2):152-60. PubMed ID: 12536204
[TBL] [Abstract][Full Text] [Related]
29. Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control.
Mathis JM; Williams BJ; Sibley DA; Carroll JL; Li J; Odaka Y; Barlow S; Nathan CO; Li BD; DeBenedetti A
J Gene Med; 2006 Sep; 8(9):1105-20. PubMed ID: 16802401
[TBL] [Abstract][Full Text] [Related]
30. The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo.
Elshami AA; Cook JW; Amin KM; Choi H; Park JY; Coonrod L; Sun J; Molnar-Kimber K; Wilson JM; Kaiser LR; Albelda SM
Cancer Gene Ther; 1997; 4(4):213-21. PubMed ID: 9253506
[TBL] [Abstract][Full Text] [Related]
31. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
32. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions.
Vrionis FD; Wu JK; Qi P; Waltzman M; Cherington V; Spray DC
Gene Ther; 1997 Jun; 4(6):577-85. PubMed ID: 9231074
[TBL] [Abstract][Full Text] [Related]
33. Involvement of Fas (CD95/APO-1) and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with herpes simplex virus thymidine kinase.
Wei SJ; Chao Y; Shih YL; Yang DM; Hung YM; Yang WK
Gene Ther; 1999 Mar; 6(3):420-31. PubMed ID: 10435092
[TBL] [Abstract][Full Text] [Related]
34. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer.
Rancourt C; Rogers BE; Sosnowski BA; Wang M; Piché A; Pierce GF; Alvarez RD; Siegal GP; Douglas JT; Curiel DT
Clin Cancer Res; 1998 Oct; 4(10):2455-61. PubMed ID: 9796978
[TBL] [Abstract][Full Text] [Related]
35. Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells.
Sharma S; Miller PW; Stolina M; Zhu L; Huang M; Paul RW; Dubinett SM
Gene Ther; 1997 Dec; 4(12):1361-70. PubMed ID: 9472560
[TBL] [Abstract][Full Text] [Related]
36. Different efficacy of in vivo herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and rat glioblastoma cells.
Berenstein M; Adris S; Ledda F; Wolfmann C; Medina J; Bravo A; Mordoh J; Chernajovsky Y; Podhajcer OL
Cancer Gene Ther; 1999; 6(4):358-66. PubMed ID: 10419054
[TBL] [Abstract][Full Text] [Related]
37. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
Hakkarainen T; Wahlfors T; Meriläinen O; Loimas S; Hemminki A; Wahlfors J
J Gene Med; 2005 Jul; 7(7):898-907. PubMed ID: 15759279
[TBL] [Abstract][Full Text] [Related]
38. Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir.
Howard BD; Boenicke L; Schniewind B; Henne-Bruns D; Kalthoff H
Cancer Gene Ther; 2000 Jun; 7(6):927-38. PubMed ID: 10880025
[TBL] [Abstract][Full Text] [Related]
39. Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK.
Varda-Bloom N; Hodish I; Shaish A; Greenberger S; Tal R; Feder B; Roitelman J; Breitbart E; Bangio L; Barshack I; Pfeffer R; Harats D
Pathobiology; 2008; 75(6):346-55. PubMed ID: 19096230
[TBL] [Abstract][Full Text] [Related]
40. Transcriptional targeting for ovarian cancer gene therapy.
Casado E; Nettelbeck DM; Gomez-Navarro J; Hemminki A; Gonzalez Baron M; Siegal GP; Barnes MN; Alvarez RD; Curiel DT
Gynecol Oncol; 2001 Aug; 82(2):229-37. PubMed ID: 11531272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
